Bristol Myers Squibb (BMY) Expected to Announce Quarterly Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY - Get Free Report) is expected to be issuing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $11.7541 billion for the quarter. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.Parties are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the firm earned $2.07 earnings per share. Bristol Myers Squibb's revenue for the quarter was up .6% compared to the same quarter last year. On average, analysts expect Bristol Myers Squibb to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $44.36 on Thursday. Bristol Myers Squibb has a 52 week low of $42.96 and a 52 week high of $63.33. The firm has a market cap of $90.29 billion, a price-to-earnings ratio of 17.89, a P/E/G ratio of 2.32 and a beta of 0.33. The firm's 50-day simple moving average is $45.92 and its 200 day simple moving average is $47.28. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. WFA of San Diego LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $49,000. Binnacle Investments Inc raised its holdings in Bristol Myers Squibb by 17.0% during the 2nd quarter. Binnacle Investments Inc now owns 1,801 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 262 shares during the last quarter. McIlrath & Eck LLC raised its holdings in Bristol Myers Squibb by 59.3% during the 2nd quarter. McIlrath & Eck LLC now owns 2,331 shares of the biopharmaceutical company's stock worth $108,000 after purchasing an additional 868 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $202,000. Institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of analyst reports. Citigroup reiterated a "neutral" rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Dbs Bank upgraded shares of Bristol Myers Squibb to a "moderate buy" rating in a research note on Thursday, October 2nd. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $57.23.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.